| Literature DB >> 31347329 |
Hye Sun Park1, Jung Soo Lim2, Sung Kil Lim3.
Abstract
PURPOSE: Muscle mass, strength, and composition determine muscle quantity and quality. However, data on muscle properties in relation to bone mass or insulin resistance are limited in Asian populations. This study aimed to investigate the relative importance of muscle measurements in regards to their relationship with lower bone mass and insulin resistance.Entities:
Keywords: Muscle; bone mass; insulin resistance; sarcopenia
Mesh:
Year: 2019 PMID: 31347329 PMCID: PMC6660447 DOI: 10.3349/ymj.2019.60.8.742
Source DB: PubMed Journal: Yonsei Med J ISSN: 0513-5796 Impact factor: 2.759
Baseline Characteristics of the Subjects
| Variable | Value |
|---|---|
| Age (yr) | 72.39±6.07 |
| Height (cm) | 154.67±4.78 |
| Weight (kg) | 56.43±8.34 |
| BMI (kg/m2) | 23.60±3.43 |
| Waist circumference (cm) | 80.36±9.23 |
| Hip circumference (cm) | 93.91±6.98 |
| Waist/hip ratio | 0.86±0.72 |
| Age at menopause (yr) | 49.52±6.23 |
| Times of exercise/week, n (%) | |
| None | 23 (12.0) |
| 1–2 | 48 (25.0) |
| 3–5 | 86 (44.8) |
| 6–7 | 35 (18.2) |
| History of spine or femur fracture, n (%) | 14 (7.3) |
| Smoking history (n) | |
| Never smoker | 188 |
| Ex-smoker or current smoker | 4 |
| Subjects with osteoporosis, n (%) | 109 (56.8) |
| Subjects with diabetes mellitus, n (%) | 55 (28.6) |
| Medication history (n) | |
| Bisphosphonates | 73 |
| SERM | 21 |
| Oral hypoglycemic agent | 51 |
| Metformin | 48 |
| Thiazolidinediones | 5 |
| Insulin | 3 |
| Glucose (mg/dL) | 107.02±18.39 |
| Glycosylated hemoglobin | 6.32±0.72 |
| Fasting insulin (µU/mL) | 8.54±6.45 |
| BUN (mg/dL) | 16.46±5.06 |
| Serum Cr (mg/dL) | 0.70±0.17 |
| AST (IU/L) | 23.34±10.00 |
| ALT (IU/L) | 19.94±11.72 |
| Total cholesterol (mg/dL) | 179.60±32.12 |
| 25-hydroxyvitamin D (ng/mL) | 34.09±11.24 |
| HOMA-IR | 2.24±1.91 |
| Spine BMD (mg/cm3) | 73.03±23.71 |
| Hip BMD (mg/cm3) | 241.487±36.72 |
| CSA of gluteus maximus muscle (mm2) | 3228.50±625.23 |
| CSA of quadriceps muscle (mm2) | 3385.60±547.74 |
| Gluteus maximus muscle attenuation (HU) | 23.74±12.32 |
| Quadriceps muscle attenuation (HU) | 47.98±7.31 |
| Hand grip strength (kg) | 19.33±4.21 |
| SPPB score | 9.93±2.23 |
BMI, body mass index; SERM, selective estrogen receptor modulators; BUN, blood urea nitrogen; Cr, creatinine; AST, aspartate transaminase; ALT, alanine transaminase; HOMA-IR, homeostatic model assessment-insulin resistance; BMD, bone mineral density; CSA, cross-sectional area; SPPB, Short Physical Performance Battery.
Values are expressed as means±standard deviations unless otherwise noticed.
Fig. 1Scatterplot analysis of BMD with muscle CSA (A and B), hand grip strength (C), SPPB score (D), and muscle attenuation (E and F). Spine BMD and hip BMD according to SPPB score (G and H). BMD, bone mineral density; CSA, cross-sectional area; SPPB, Short Physical Performance Battery.
Correlation between BMD and Muscle Parameters
| Spine BMD | Spine BMD | Hip BMD | ||
|---|---|---|---|---|
| β (SE) | β (SE) | |||
| Gluteus maximus muscle area | 0.218 (0.003) | 0.006 | 0.275 (0.004) | <0.001 |
| Model 1 | 0.203 (0.003) | 0.015 | 0.207 (0.005) | 0.014 |
| Model 2 | 0.192 (0.003) | 0.026 | 0.208 (0.005) | 0.016 |
| Model 3 | 0.224 (0.003) | 0.012 | 0.228 (0.005) | 0.011 |
| Quadriceps muscle area | 0.259 (0.003) | 0.001 | 0.273 (0.005) | 0.001 |
| Model 1 | 0.172 (0.003) | 0.038 | 0.189 (0.005) | 0.024 |
| Model 2 | 0.220 (0.004) | 0.011 | 0.202 (0.006) | 0.021 |
| Model 3 | 0.196 (0.004) | 0.026 | 0.184 (0.006) | 0.041 |
| Hand grip strength | 0.263 (0.431) | 0.001 | 0.268 (0.678) | 0.001 |
| Model 1 | 0.169 (0.463) | 0.041 | 0.191 (0.726) | 0.022 |
| Model 2 | 0.191 (0.491) | 0.031 | 0.196 (0.781) | 0.027 |
| Model 3 | 0.201 (0.506) | 0.027 | 0.177 (0.802) | 0.050 |
| SPPB score | 0.415 (1.168) | <0.001 | 0.332 (1.880) | 0.004 |
| Model 1 | 0.224 (1.265) | 0.054 | 0.184 (2.046) | 0.129 |
| Model 2 | 0.174 (1.379) | 0.160 | 0.200 (2.545) | 0.153 |
| Model 3 | 0.205 (1.409) | 0.107 | 0.215 (2.691) | 0.146 |
BMD, bone mineral density; SPPB, Short Physical Performance Battery; BMI, body mass index; eGFR, estimated glomerular filtration rate; SERM, selective estrogen receptor modulators; AST, aspartate transaminase; ALT, alanine transaminase; HOMA-IR, homeostatic model assessment-insulin resistance.
Model 1 adjusted for age and BMI; model 2 adjusted for model 1 parameters+eGFR, HOMA-IR, AST, ALT, total cholesterol and 25-hydroxyvitamin D; model 3 adjusted for model 2 parameters+physical activity (exercise/week), medication history (SERM, metformin or thiazolidinediones) and smoking history.
Fig. 2Scatterplot analysis of HOMA-IR with muscle CSA (A and B), hand grip strength (C), SPPB score (D), and muscle attenuation (E and F). HOMA-IR, homeostatic model assessment-insulin resistance; CSA, cross-sectional area; SPPB, Short Physical Performance Battery.
Correlation between HOMA-IR and Muscle Attenuation
| HOMA-IR | ||
|---|---|---|
| β (SE) | ||
| Gluteus maximus muscle attenuation | −0.194 (0.013) | 0.018 |
| Model 1 | −0.204 (0.013) | 0.016 |
| Model 2 | −0.212 (0.012) | 0.008 |
| Model 3 | −0.199 (0.013) | 0.013 |
| Quadriceps muscle attenuation | −0.292 (0.021) | <0.001 |
| Model 1 | −0.295 (0.021) | <0.001 |
| Model 2 | −0.278 (0.020) | <0.001 |
| Model 3 | −0.230 (0.021) | 0.004 |
HOMA-IR, homeostatic model assessment-insulin resistance; BMI, body mass index; eGFR, estimated glomerular filtration rate; SERM, selective estrogen receptor modulators; AST, aspartate transaminase; ALT, alanine transaminase; BMD, bone mineral density.
Model 1 adjusted for age and BMI; model 2 adjusted for model 1 parameters+eGFR, AST, ALT and total cholesterol; model 3 adjusted for model 2 parameters+hip BMD, physical activity (exercise/week), medication history (SERM, metformin or thiazolidinediones), smoking history and fracture history.
Fig. 3Muscle parameters in subjects with osteoporosis (A, B, and C) and diabetes (E, E, and F). Muscle CSA is shown in (A) and (D), physical performance in (B) and (E), and muscle composition in (C) and (F). *p≤0.05 versus non-osteoporotic (A, B, and C) or non-diabetic group (D, E, and F). CSA, cross-sectional area; HGT, hand grip test; SPPB, Short Physical Performance Battery.